Imugene receives DIR licence for VAXINIA Phase 1 trial expansion in Australia

Be the First to Comment Read
Sponsored

Imugene receives DIR licence for VAXINIA Phase 1 trial expansion in Australia

 Imugene receives DIR licence for VAXINIA Phase 1 trial expansion in Australia
Image source: Company Announcement

Highlights

  • Imugene Limited has secured the DIR licence, essential for expanding its VAXINIA Phase 1 clinical trial within Australia.
  • The licence has been granted by the Australian Government’s Office of the Gene Technology Regulator (OGTR).
  • The clinical trial started in May this year and is likely to conclude in around 24 months.

Imugene Limited (ASX:IMU), an eminent player marking transformational progress in cancer treatment, has been granted the DIR licence by the Australian Government’s Office of the Gene Technology Regulator (OGTR). The licence holds prominence for expansion of the company’s VAXINIA Phase 1 clinical trial within Australia. It is an essential element needed for the Australian regulatory framework for matters relating to the intentional release of organisms which are genetically modified into the environment.

The licence is titled ‘Clinical Trial of a Genetically Modified (GM) Chimeric Orthopoxvirus (CF33-hNIS) as a Cancer Treatment’.

An overview of Phase 1 VAXINIA trial

Image Source: Company Announcement

Imugene’s Phase 1 VAXINIA clinical trial is titled “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).”

The company initiated the multicenter Phase 1 VAXINIA trial in May this year at its sites based in the United States. A total of 100 patients will be enrolled for the study across 10 clinical trial sites in Australia and the United States.

In preclinical laboratory as well as animal models, City of Hope-developed oncolytic virus, CF33-hNIS VAXINIA, has been shown to shrink breast, colon, lung, ovarian, and pancreatic cancer tumours. As of now, a low dose of VAXINIA has been delivered to the enrolled subjects having metastatic or advanced solid tumours. All the recruited patients have had at least two prior lines of the standard of care treatment.

The study is expected to be conducted for a period of around two years.


Image Source: ©2022 Kalkine Media®, Data Source: Company Announcement

IMU shares were trading at AU$0.220 on 21 September 2022.

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK